TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02790632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-1962 (nimodipine microparticles)
Description: Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
Study: NCT03016832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo drug that simulates Irbesartan tablets
Description: Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing

Intervention type: DRUG
Group type: OTHER
Intervention: irbesartan tablets
Description: irbesartan tablets 150mg /qd, oral dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan tablets
Description: irbesartan tablets 150mg /qd, oral dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drug that simulates HuangKui capsule
Description: Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuangKui Capsule
Description: HuangKui Capsule 2.5g/tid, oral dosing.

Intervention type: DRUG
Group type: OTHER
Intervention: HuangKui Capsule
Description: HuangKui Capsule 2.5g/tid, oral dosing.
Study: NCT03087110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matched sibling donor cord blood cell infusion
Description: Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (\>1x10\^7 cells/kg)
Study: NCT03796143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Mindfulness and Acceptance Workbook for Depression
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Mindfulness and Acceptance Workbook for Depression
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Cognitive Behavioral Workbook for Depression
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
Study: NCT02710110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iowa Oral Pressure Instrument
Description: The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Iowa Oral Pressure Instrument
Description: The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Capsaicin
Description: A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds.
Study: NCT03137173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole medocaril
Description: ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin+aztreonam
Description: Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit.
Study: NCT01276873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal aspiration close system
Description: use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
Study: NCT01509157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDRS System (Remote & Safety diabetes management system)
Description: Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
Study: NCT02053597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: All patients will receive four cycles of doxorubicin (A) (50 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
Study: NCT02062099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment
Study: NCT01304927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol and calcium
Description: Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose maltodextrin Arachidis oil
Study: NCT03377166

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bucket test and Smartphone-based evaluation of SVV
Description: Bucket test and Smartphone-based evaluation of SVV

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bucket test and Smartphone-based evaluation of SVV
Description: Bucket test and Smartphone-based evaluation of SVV
Study: NCT04335357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBR-760
Description: TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03608462

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(DLPFC)
Description: high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation(LPC)
Description: high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
Study: NCT02653989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDV9300
Description: MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
Study: NCT01854957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: Single dose of 1-2 x 1000000 cells/Kg body weight
Study: NCT03125902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Description: Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Placebo
Description: Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
Study: NCT03796143

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Cognitive Behavioral Workbook for Depression
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
Study: NCT03467984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBVE
Description: Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: 13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
Study: NCT01816906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Footwear :PU
Description: One group of patients will receive Footwear with PU insoles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Footwear: MCP
Description: One group of patients will receive footwear with MCP insoles
Study: NCT03125902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
Study: NCT00525629

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: 48 Grams of Walnuts Daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control Diet with No Walnuts
Study: NCT01533467

Intervention type: DEVICE
Group type: OTHER
Intervention: Perineal protection device
Description: Use of the device during delivery and inspection afterwards to see the tears.
Study: NCT02966795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Fixed-dose combination tablets taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Fixed-dose combination tablets taken orally once a day.
Study: NCT02066506

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: asymptomatic group
Description: 2 visits with MRI

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: asymptomatic group
Description: 2 visits with MRI

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: symptomatic group
Description: 2 visits with MRI

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: symptomatic group
Description: 2 visits with MRI
Study: NCT03043027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivicaine
Description: local anesthetic
Study: NCT03125902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
Study: NCT01034618

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein hydrolyzation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein hydrolyzation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein hydrolyzation
Study: NCT00644618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
Study: NCT04589117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth
Study: NCT03043027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline injection
Study: NCT03913650

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 0.25% bupivacaine
Description: nerve block procedure will be decided by patients' will for post-op pain
Study: NCT03310099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing daily unsaturated fatty acid consumption
Description: Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
Study: NCT00644618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 125I brachytherapy PLUS gemcitabine
Description: 125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
Study: NCT02653495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
Study: NCT02790632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nimodipine
Description: Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
Study: NCT02779426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Daily text messages with information about atopic dermatitis and treatment reminders.
Study: NCT01409772

Intervention type: DRUG
Intervention: Ethanol Lock
Description: Ethanol Lock
Study: NCT04545086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Based Education, Music Therapy
Description: Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
Study: NCT03913650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine
Description: nerve block procedure will be decided by patients' will for post-op pain
Study: NCT03222596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise programme includes breathing and upper limbs exercises.
Study: NCT03251040

Intervention type: DEVICE
Group type: OTHER
Intervention: Autologous activated fibrin sealant
Description: Application of fibrin sealant
Study: NCT01515475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Glasses
Description: Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
Study: NCT02646332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (dexlan+amox+clar+metr)+(dexlan+amox)
Description: a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexlan+clarith+amox+metro
Description: dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
Study: NCT04165772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042 or Dostarlimab
Description: Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: TSR-042 or Dostarlimab
Description: Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine or 5-FU
Description: Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
Study: NCT01740089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algeron
Description: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algeron
Description: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Study: NCT04165772

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
Study: NCT02865460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
Study: NCT00253721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days
Study: NCT01563224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 10mg
Description: Baclofen 10mg single dose po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 60mg
Description: Baclofen 60mg single dose po
Study: NCT01573338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roniciclib (BAY1000394)
Description: oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
Study: NCT00162318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Gefitinib
Description: IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
Study: NCT03479918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH-21
Description: R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-BL-M-04
Description: R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH-21 + auto-SCT
Description: R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-BL-M-04 + auto-SCT
Description: R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
Study: NCT00814749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: midureteral sling
Description: midureteral sling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical therapy or conservative
Description: midureteral sling or conservative; medication, physiotherapy
Study: NCT04494399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1b
Description: 5-day course of daily subcutaneous injection of interferon β-1b 16 million IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 5-day course of oral ribavirin 400mg twice daily
Study: NCT03430518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1.12g given IV on day 1 every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.